Board of Directors
Michael D. Goldberg
Chairman of the Board, CareDx, Inc.
Michael Goldberg has served as a member and chairman of our board of directors since November 2011. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as chairman until August 2001 and as chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as chief executive officer until its sale to Bristol-Myers Squibb in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm, Sevin Rosen Management Company, from 1985 to 1987, where he established the firm’s life science practice, and was director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the board of directors of numerous companies in the biotech and health sciences industry, and currently serves as executive chairman of DNAnexus, Inc. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic, and public policy institutions in biotechnology and finance, including the board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the board of the Western Association of Venture Capitalists, the advisory boards of the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.
Chairperson and Chief Executive Officer for N-of-One
Chris Cournoyer is presently a strategic advisor to QIAGEN and prior to that served as the Chairperson and Chief Executive Officer for N-of-One. Chris led the transformation of N-of-One’s patient concierge business to a leading molecular decision support company in oncology. Under her leadership she raised capital, created the digital strategy for interpreting molecular diagnostic tests and led the strategic sales process resulting in a successful sale to QIAGEN in 2019. Prior to joining N-of-One, Chris was the Vice President of Clinical Analytics for Optum responsible for clinical EHR solutions and the clinical decision support solutions. Prior to joining Optum through the acquisition of Picis in 2010, Chris was the President and COO for Picis, Inc., a global leader in the Healthcare IT market, offering digital EHR solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Previous to Picis, Chris was responsible for all analytical solutions serving the retail industry at Harte Hanks. From 1995- 2001, Chris held technology roles at Lotus as Chief Information Officer and at IBM where she was Vice President of Global Business Transformation responsible for the order to cash operations and for the Information Technology function for an $8B software business for IBM. Chris has provided technology expertise to three public boards including Stride Rite, GTECH, and BJ’s Wholesale group and has been a director for Emerson Hospital. Chris holds a B.S in Business Administration, University of Massachusetts, an MA Economics, Northeastern University and has attended MIT’s Executive Education Program.
Managing Director, MM Dillon & Co.
George W. Bickerstaff, III has served as a member of our board of directors since April 2014. Mr. Bickerstaff is currently the managing director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to that Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including chief financial officer of Novartis Pharma AG from October 2000 to May 2005. Previously, George held senior finance and operating roles with various global companies including, IMS, Dun & Bradstreet and General Electric. Mr. Bickerstasff received a BS in engineering and a BA in business administration from Rutgers University in 1978.
Dr. Fred Cohen, MD, DPhil
Senior Managing Director, Vida Ventures
Fred E. Cohen has served as a member of our board of directors since January 2003. He is a founder and senior managing director of Vida Ventures, a biotechnology venture capital group. Dr. Cohen is a senior advisor of TPG, a global private equity firm. Dr. Cohen joined TPG in 2001, and serves as head of TPG’s biotechnology group. Dr. Cohen was a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco from 1988 to 2016. Dr. Cohen has played a role on the boards of directors or scientific advisory boards of a variety of biotechnology companies. He currently serves on the board of directors of Veracyte, Inc., BioCryst Pharmaceuticals, Inc., and Five Prime Therapeutics, Inc., as well as multiple other private and public companies. He received his MD from Stanford University, his DPhil in Molecular Biophysics from Oxford University as a Rhodes Scholar, and his BS in Molecular Biophysics and Biochemistry from Yale University. Dr. Cohen was elected to the Institute of Medicine and the National Academics in 2004 and the American Academy of Arts and Sciences in 2008. Dr. Cohen also serves a fellow of the American College of Physicians since 1989, a member of the American Society for Clinical Investigation and the Association of American Physicians and is the recipient of several awards and honors including the Burroughs-Wellcome New Initiatives in Maleria Award, the LVMH Science Pour L’Art Price (shared with Stanley Prusiner), and Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation.
Grace E. Colón, PhD
President & CEO – InCarda Therapeutics, Inc.
Grace E. Colón, has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company developing therapeutics for cardiovascular conditions since 2013. She is also Executive Chairman (formerly CEO) of ProterixBio, is on the board of Cocoon Biotech, the advisory board of the Miller Center for Social Entrepreneurship at Santa Clara University and served on the boards of Paradigm Diagnostics and PerceptiMed. Previously, she was a partner at New Science Ventures, a New York based venture capital firm. From 2010-2012, she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. At Gilead she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was Vice President, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., and an engineer with Merck & Co. in France and in Rahway, NJ. Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow, and holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
CEO, Octave Bioscience
William Hagstrom has served as a member of our board of directors since March 2015. He is currently the founder and CEO of Octave Bioscience, an early stage molecular diagnostics company focused on neurodegenerative diseases and conditions. In 2007, Mr. Hagstrom secured financing for Crescendo Bioscience, a specialty diagnostics company focused on autoimmune and inflammatory diseases managed by rheumatologists. Serving as president and chief executive officer, he led the development of the company’s product pipeline, operations infrastructure and commercial strategy. In 2014, Crescendo was acquired by Myriad Genetics as a wholly owned subsidiary. Prior to founding Crescendo Bioscience, Mr. Hagstrom was president of Alpha BioPartners, a strategic consulting firm for early stage biotechnology companies. While at Alpha, Mr. Hagstrom co-founded Biolytx Pharmaceuticals and Altheus Therapuetics. Mr. Hagstrom also served as interim CEO of Selexys Pharmaceuticals and Inoveon. Previous to this he was Chairman and CEO of UroCor, a specialty diagnostics company focused on urological cancers and complex diseases. Under Mr. Hagstrom’s leadership, the company was an Inc. 500 company from 1992, 1993, 1994 and 1995, before becoming public in 1996. Previously, Mr. Hagstrom held executive positions at some of the largest multinational healthcare companies in the world, including Becton Dickinson, American Hospital Supply and Baxter International, where he served as Vice President of the company’s billion-dollar scientific products division. Mr. Hagstrom has served on a variety of Boards over the last 15 years, including Prometheus Laboratories. Mr. Hagstrom received a BS degree in business management from Bob Jones University.
Peter Maag, PhD
Chief Executive Officer, CareDx, Inc.
Peter Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Peter was President of Novartis Diagnostics. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Peter also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he served as the Head of Strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Peter worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds a supervisory board position at Phoenix Pharma SE and serves on the board of the Personalized Medicine Coalition in Washington, DC. Peter studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany.
Dr. Ralph Snyderman, MD
Chancellor Emeritus and James B. Duke Professor of Medicine, Duke University
Ralph Snyderman has served as a member of our board of directors since May 2005. Dr. Snyderman has held the position of chancellor emeritus and James B. Duke Professor of Medicine at Duke University since July 2004. From January 1989 to June 2004, he served as chancellor for health affairs at the Duke University School of Medicine, and was the founding CEO and president of the Duke University Health System. From January 2006 to November 2009, he consulted for New Enterprise Associates, a venture capital firm, as a venture partner. He previously served on the boards of directors of The Procter & Gamble Company, Pharmaceutical Product Development, LLC (PPD), Trevena, Inc., Crescendo Bioscience, Inc. and Targacept, Inc. He currently serves on the boards of Nodality, Inc., Press Ganey Associates, Inc., and Liquida Technologies, Inc. Dr. Snyderman is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002, the Institute of Medicine, and the American Academy of Arts & Sciences. Dr. Snyderman holds a BS in pre-medical studies from Washington College, an MD from the State University of New York, Downstate Medical Center, and completed an internship and residency in Medicine at Duke University.